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Abstract
Background: TGF-β1 is an important angiogenic factor involved in the different aspects of angiogenesis
and vessel maintenance. TGF-β signalling is mediated by the TβRII/ALK5 receptor complex activating the
Smad2/Smad3 pathway. In endothelial cells TGF-β utilizes a second type I receptor, ALK1, activating the
Smad1/Smad5 pathway. Consequently, a perturbance of ALK1, ALK5 or TβRII activity leads to vascular
defects. Mutations in ALK1 cause the vascular disorder hereditary hemorrhagic telangiectasia (HHT).
Methods: The identification of ALK1 and not ALK5 regulated genes in endothelial cells, might help to
better understand the development of HHT. Therefore, the human microvascular endothelial cell line
HMEC-1 was infected with a recombinant constitutively active ALK1 adenovirus, and gene expression was
studied by using gene arrays and quantitative real-time PCR analysis.
Results: After 24 hours, 34 genes were identified to be up-regulated by ALK1 signalling. Analysing ALK1
regulated gene expression after 4 hours revealed 13 genes to be up- and 2 to be down-regulated. Several
of these genes, including IL-8, ET-1, ID1, HPTPη and TEAD4 are reported to be involved in angiogenesis.
Evaluation of ALK1 regulated gene expression in different human endothelial cell types was not in
complete agreement. Further on, disparity between constitutively active ALK1 and TGF-β1 induced gene
expression in HMEC-1 cells and primary HUVECs was observed.
Conclusion: Gene array analysis identified 49 genes to be regulated by ALK1 signalling and at least 14
genes are reported to be involved in angiogenesis. There was substantial agreement between the gene
array and quantitative real-time PCR data. The angiogenesis related genes might be potential HHT modifier
genes. In addition, the results suggest endothelial cell type specific ALK1 and TGF-β signalling.
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Background
Vascular development and homeostasis are regulated by a
number of cytokines including members of the transform-
ing growth factor-beta (TGF-β) superfamily that resemble
a group of structurally related secreted polypeptides that
regulate numerous cellular activities including prolifera-
tion, differentiation, migration, extracellular matrix depo-
sition and apoptosis [1,2]. This family consists of over 35
cytokines that include TGF-β1, -β2 and -β3, as well as
activins, inhibins, nodals and the large group of bone
morphogenetic proteins (BMPs). All have crucial roles in
development and tissue homeostasis and their impor-
tance is further demonstrated by their involvement in dif-
ferent diseases [1,3].
Signalling is mediated by a class of single transmembrane
domain serine/threonine kinase receptors, types -I and -II,
that initiate phosphorylation of co-transcription factors of
the Smad protein family [2,4]. There are five type II recep-
tors and 7 type I receptors designated as activin receptor-
like kinases (ALKs), ALK1-7. Ligand binding induces com-
plex formation between type I and type II receptors, upon
which the constitutively active kinase of the type II recep-
tor phosphorylates the type I receptor in its so called 'GS'
domain. Activated type I receptor in turn phosphorylates
receptor-regulated Smads (R-Smads; Smad-1, -2, -3, -5
and -8), which bind to the Smad4 protein, translocate to
the nucleus and regulate gene expression in concert with
other transcription factors. A third class of Smads, the
inhibitory Smads (I-Smads; Smad-6 and -7), oppose the
signalling activity of R-Smads and Smad4 by different
mechanisms. Each TGF-β family member binds to a char-
acteristic set of type I and II receptors and based on this
combination activates a specific R-Smad.
In angiogenesis the formation of new blood vessels by de-
novo capillary development from pre-existing vascular
endothelium, vessel assembly, maturation and remodel-
ling is based on a finely balanced series of events in which
TGF-β plays a pivotal role, both as a pro-angiogenic (acti-
vation phase) as well as an anti-angiogenic (resolution-
maintenance phase) cytokine [5,6]. This bi-phasic activity
is dose-dependent [7,8]. Many angiogenic disorders most
likely result from an unbalanced activity or loss of differ-
ent angiogenic factors. Hereditary hemorrhagic tel-
angiectasia (HHT) is characterized by telangiectases and
arteriovenous malformations (AVMs) typically found in
the skin and mucocutaneous tissues [9-11]. Telangiectases
and AVMs show abnormal connection between arteries
and veins that is devoid of intervening capillaries and has
a more vein-like phenotype [12]. Previous studies have
shown that HHT is caused by mutations in either endoglin
(CD105) or ALK1 [13,14]. More recently, mutations in
Smad4 were reported to cause a syndrome consisting of
both juvenile polyposis and hereditary haemorrhagic tel-
angiectasia phenotypes [15].
Endoglin binds TGF-β1 and -β3 isoforms that requires
presence of the TGF-β type II receptor [16,17]. ALK1, a
type I receptor for TGF-β1 and -β3 [6,18], activates the
BMP signalling pathway by phosphorylating Smad1/5
[19,20]. Both endoglin and ALK1 are predominantly
expressed by endothelial cells. Studies with mice have
shown that a homozygous knock-out of either endoglin
or ALK1 is embryonically lethal due to vascular defects
[21-25]. Heterozygous endoglin as well as ALK1 mice are
viable, but a percentage of those develop a phenotype
similar to that observed in HHT patients [25,26].
Recent studies in endothelial cells have shown that TGF-β
signals through ALK1, activating the Smad1/5 pathway,
and through ALK5, activating the Smad2/3 pathway [6].
These two pathways have in a dose-dependent manner
opposing effects on endothelial cell behaviour: ALK1 pro-
motes cell proliferation and migration, whereas ALK5
inhibits both processes. Low TGF-β concentrations induce
ALK1 signalling, which needs and is promoted by endog-
lin [27,28] and in addition requires the presence of ALK5
[29]. In contrast, high TGF-β concentrations activate the
ALK5 pathway.
The lethality of endoglin or ALK1 deletion in mice points
to essential roles for both in normal and aberrant angio-
genesis but their exact roles are still largely unknown. To
understand the function of endoglin and ALK1 in these
processes requires elucidation of their activities in cell
adhesion, migration, and importantly gene regulation.
Gene arrays can simultaneously examine many hundreds
or thousands of genes but suffer from being only semi-
quantitative. Also, many changes are difficult to decipher
due to high background that makes interpretation uncer-
tain. Quantitative real-time (qRT)-PCR sensitively detects
quantitative changes in mRNA but cannot process simi-
larly large numbers of genes
In order to identify target genes specific to ALK1 signal-
ling, we over-expressed ALK1 in the human microvascular
endothelial cell line HMEC-1 using recombinant adenovi-
rus carrying a constitutively active form of ALK1, thus
masking ALK5 responses. We then compared gene array
hybridisation data representing 5,600 human full-length
genes, with semi-quantitative and qRT-PCR analyses of
transcripts identified as altered by the Affymetrix Gene-
Chip™ arrays. We found 34 genes to be up-regulated by
constitutively active ALK1 signalling after 24 hours and 15
genes being dys-regulated (13 up- and 2 down-regulated)
after 4 hours. Consistent with the vascular disorder HHT,
at least 14 of the ALK1 response genes are reported to be
involved in angiogenesis, vascular disorders or the home-BMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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ostasis of the vascular system. We found substantial agree-
ment between the gene array and qRT-PCR data, but there
were a number of disparate results regarding TGF-β
induced signalling and constitutively active receptor sig-
nalling depending on the endothelial cell type.
Methods
Cell culture and growth factor
HMEC-1 cell line (derived from human dermal microvas-
cular endothelial cells) [30] was cultured in MCDB-131
containing 15% human serum, penicillin (100 U/ml),
and streptomycin (100 µg/ml). ECRF24 cell line (derived
from human umbilical vein endothelial cells) [31] was
cultured in equal volumes of M199 and RPMI 1640
medium containing 2 mM glutamine, penicillin (100 U/
ml), streptomycin (100 µg/ml), G418 (100 µg/ml), and
20% human serum. Primary human umbilical cord vein
endothelial cells (HUVECs) were cultured in M199
glutamax containing HEPES (16 mM), heparin (6.4 U/
ml), gentamicin (80 µg/ml), PD-ECGF (20 µg/ml), 10%
foetal calf serum (FCS) and 10% human serum. Cre8 cells
and HEK 293A cells were cultured in Dulbecco's modified
Eagle's medium with 10% FCS, penicillin (100 U/ml),
and streptomycin (100 µg/ml). All cells were cultured at
37°C in a humidified atmosphere of air containing 5%
CO2. Media, media supplements and FCS were obtained
from PAA Laboratories (Germany) and Invitrogen (Ger-
many). TGF-β1 and PD-ECGF were obtained from R&D
Systems (Wiesbaden, Germany).
Recombinant adenovirus
The cDNA for constitutively active ALK1 (ALK1QD-HA, C-
terminal HA tagged) was subcloned into the HindIII/
BamHI sites of the Adlox vector, which possesses one loxP
site, a left inverted terminal repeat followed by a packag-
ing sequence (Ø), the human cytomegalovirus immedi-
ate-early promoter, a multiple cloning site, and a right
inverted terminal repeat. The Adlox vector serves as the
shuttle vector for generating recombinant adenovirus via
the Cre-lox system [32]. Using CaPO4, Cre8 cells were co-
transfected with the AdLox-ALK1QD plasmid DNA (2.1
µg) and DNA (2.1 µg) of the E1-deleted φ5 virus (adeno-
virus type 5 engineered with two lox-P sites flanking the
packaging site), creating the AdALK1QD virus. For control
infections virus containing no insert (AdCMV3) was cre-
ated in addition to a virus expressing the bacterial β-galac-
tosidase gene named AdLacZ. Following amplification of
the recombinant virus in Cre8 cells, a large-scale virus
preparation was made from infected HEK 293A cells. The
cells were harvested 2 days after infection, sedimented
(1000 × g, 10 min) and the cell pellet was resuspended in
10 ml of OPTI-MEM (Gibco-BRL), freeze-thawed three
times, and resedimented. The resulting lysate (~10 ml)
was loaded onto a two-step CsCl gradient (10 ml of CsCl
at 1.4 g/cm3 overlaid with 10 ml of CsCl at 1.2 g/cm3, and
the gradient was centrifuged (20,000 rpm, 2 hr, 15°C,
SW28 rotor). Viral particles in the 1.3 g/cm3 region were
harvested and the volume was brought to 21 ml with a
solution of 1.3 g/cm3 CsCl. In a tube the viral solution was
overlaid onto a cushion of 1.5 ml of 1.5 g/cm3 CsCl solu-
tion, and centrifuged (40,000 rpm, 12–16 hr, 15°C in an
SW41 rotor). The resulting viral band (1.5–2.5 ml) was
harvested and dialyzed at 4°C three times against 1 litre of
buffer using a Slide-A-Lyzer (Pierce Chemical, Indianapo-
lis, IN) and storage buffer (10 mM Tris-HCl, pH 7.4, 0.9%
NaCl, 1 mM MgCl2, 1 mM CaCl2, with 10% glycerol in the
last change) then aliquoted and stored at -80°C. Stock
concentrations (viral particles [vp] per ml) were calculated
from OD260 × dilution × 1.1 × 1012, with OD260/280 of 1.2–
1.3.
Viral infection
In order to test whether HMEC-1 cells can be infected by
adenovirus, cells were incubated with AdLacZ at different
multiplicity of infection (MOIs). An MOI of 50 was estab-
lished to be optimal for 100% infection efficiency demon-
strated by X-Gal staining (data not shown). Further on, an
MOI of 50 displayed no effect on cell growth or morphol-
ogy when tested for AdLacZ, AdCMV3 and more impor-
tant for AdALK1QD, whereas MOIs of >100 affected
cellular growth and induced partial cell death for all three
tested recombinant adenoviruses. Once optimal MOI was
established endothelial cells were seeded into a 100 mm
dish at a density of ~4 × 106 cells. The next day cells were
infected with an MOI of ~50 with the indicated recom-
binant adenovirus. In brief, medium was aspirated and
exchanged for medium with no serum containing the
virus. After 30 min of incubation the medium was aspi-
rated and exchanged for fresh medium containing serum.
Cells were then further incubated for the indicated time.
RNA isolation and sample preparation for GeneChip™ 
hybridization
Total RNA from cells either infected with AdCMV3 or
AdALK1QD was isolated with the RNeasy Mini Kit (Qia-
gen) according to the manufacturer's instruction. Hybrid-
ization targets were prepared from 10 µg of total RNA
according to standard Affymetrix™ protocols (see Affyme-
trix™ webpage [33]). Briefly, first strand cDNA synthesis
was generated using a T7-linked oligo-dT primer, fol-
lowed by second strand synthesis. An in vitro transcription
reaction was performed to generate cRNA containing
biotinylated UTP and CTP, which subsequently was frag-
mented chemically at 95°C for 35 min. The fragmented,
biotinylated cRNA was hybridized in MES buffer (2-[N-
morpholino]ethansulfonic acid) containing 0.5 mg/ml
acetylated bovine serum albumin to the Affymetrix
Human 6800 GeneChip™ at 45°C for 16 hr, according to
the Affymetrix protocol. Arrays were washed and stained
with streptavidin-phycoerythrin (SAPE, MolecularBMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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Probes). Signal amplification was performed using a
biotinylated anti-streptavidin antibody (Vector Laborato-
ries, Burlingame, CA) at 3 µg/ml, followed by a second
staining with SAPE. Normal goat IgG (2 mg/ml) was used
as the blocking agent.
Measurement scans were performed using an Affymetrix
GeneChip™ confocal scanner and the MAS 4.0 average dif-
ferences were computed. Scaling factors were determined
for each hybridization based on a target intensity of 500.
Scaled average difference values were used in generating
comparison analysis in the Affymetrix MAS 4.0 software.
Briefly, in the Affymetrix MAS 4.0 comparison analysis,
one array is designated as the baseline (reference sample)
and the other as an experiment (test sample). The analysis
compares the difference values (perfect match-mismatch)
of each probe pair in the baseline array (mock infected
cells) to its equivalent on the experiment array
(AdALK1QD infected cells) and based on this a fold change
was determined. Further explanation of the comparison
analysis can be found at the Affymetrix™ webpage [33]. All
GeneChip™ raw data generated from this study can be
seen online [34] (24 hour experiments: 153_22hrCMV
[reference sample] versus 154_22hrALK1 [test sample],
155_22hrCMV [reference sample] versus 156_22hrALK1
[test sample], 91_22hrCMV [reference sample] versus
92_22hrALK1 [test sample]; 4 hour experiments:
66_4hrCMV [reference sample] versus 63_4hrALK1 [test
sample], 89_4hrCMV [reference sample] versus
90_4hrALK1 [test sample]).
RNA isolation and semi quantitative RT-PCR
Total RNA from AdCMV3, AdLacZ or AdALK1QD infected
or non-infected cells and total RNA from TGF-β treated or
non-treated cells was isolated with the RNeasy Mini Kit
(Qiagen) according to the manufacturer's instruction. For
further semi quantitative RT-PCR (sqRT-PCR) or qRT-PCR
2  µg of total RNA was reverse transcribed by random
priming with hexamers and Oligo-dT primining (T18N)
using the Omniscript RT Kit (Qiagen) according to the
manufacturer's instruction. The resulted single strand
cDNA was stored in a 50 µl volume at -20°C until use.
For sqRT-PCR 1 µl of the single strand cDNA was used in
a 20 µl PCR reaction mixture containing 10 pmol of a
gene specific primer pair (see Table 1), 1x PCR buffer (Inv-
itrogen) containing 2.5 mM MgCl2, 200 µm dNTPs, 1
Unit Platinum Taq (Invitrogen). PCR conditions were as
following: initial denaturing at 95°C for 5 min, 30 cycles
of 30 sec denaturing at 95°C, 30 sec primer annealing at
primer specific temperature, 30 sec elongation at 72°C.
After 30 cycles final elongation step for 5 min. Equal
amounts of PCR products were separated on 1.5 % agar-
ose gels and visualized by ethidium bromide staining.
Relative quantification of gene expression using the 
comparative method (∆∆CT)
Quantitative real-time PCR (qRT-PCR) was used to meas-
ure gene expression levels in HMEC-1, HUVEC and
ECRF24 cell lines under various conditions. For gene
expression analysis, pre-designed gene-specific primer
pairs were selected for 17 target genes and 1 endogenous
control from a comprehensive catalogue of pre-designed
assays named Assays-on-Demand™ (Applied Biosystems)
(see Table 2). All assays were based on TaqMan hydrolysis
probes labeled with FAM™ (green fluorescent fluorophore
6-carboxyfluorescein). Assays were performed on an ABI
PRISM® 7900 HT Sequence Detection System (384-well
Table 1: Gene-specific oligonucleotides for sqRT-PCR. Primer sets were designed across exon-exon boundaries to avoid amplification 
of genomic DNA in the cDNA samples that might contain traces of genomic DNA. ALK1 Primers were also used for qRT-PCR 
analyses (own assay).
Gene Forward primer (5' – 3' 
orientation)
Reverse primer (5' – 3' 
orientation)
PCR annealing Temp (°C)
TLS TTGAGTCTGTGGCTGATTAC CACTGGTTGCATTCATTCCT 56
GADD153 GTCTAAGGCACTGAGCGTAT TGGGGAATGACCACTCTGTT 58
IL-8 GATTGAGAGTGGACCACACT TCGGATATTCTCTTGGCCCT 58
SMAD6 GTCTTACACTGAAACGGAGG AGCTGATGCGGACGCTGTTG 58
COL5A1 TCGATCCTAACCAAGGATGC TGTGACGCTTCACCGAAGTC 58
HEF1 GAAGAATGGGCCGGAGAGCA GGGAAATGAAATGGGTCTCA 56
TLR4 ACAAAATCCCCGACAACCTC ATGTAGAACCCGCAAGTCTG 58
ET-1 CCTGGACATCATTTGGGTCA AGGGCTTGCCTTTCAGCTTG 58
CARP ACCGCTATAAGATGATCCGA AATGAAGCTCTGCTCACCAG 56
HPTPη GGGCACTTTCATTGCCATTG CATAGCTCCCTTTTCCTGGT 58
DNAJB1 ACTACTACCAGACGTTGGGC CCGCTTGTGGGAGATTTTCG 60
MGSA GGGAATTCACCCCAAGAACA ATCACAGTGGCTGGCATGTT 58
c-myc AGGCTATTCTGCCCATTTGG CCACATACAGTCCTGGATGA 58
ALK1 GCAACCTGCAGTGTTGCATC CGGATCTGCTCGTCCAGCAC 60
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 60BMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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block module). For the ALK1 construct a second assay uti-
lising SYBR Green I® was used in conjunction with the
primer pair designed for the sqRT-PCR detection of
ectopic ALK1 expression along with a SYBR Green I® assay
designed to GAPDH. The SYBR Green I® assays were per-
formed on an ABI PRISM® 7700 Sequence Detection Sys-
tem (96-well block module).
Once RNA was extracted and reverse transcribed the cDNA
was diluted 1 in 50 and assayed in 20 µl reaction volumes.
For the assays on demand each reaction comprised of 5 µl
cDNA, 10 µl 2x qPCR Master Mix with uracil-N-glycosy-
lase (Eurogentec), 1 µl 20x Primer/Probe Assay mix
(Applied Biosystems), the SYBR Green I® assays comprised
of 5 µl cDNA, 10 µl 2x SYBR Green I® Master Mix (Applied
Biosystems) and 10 pmol each primer. Samples were then
amplified on an ABI PRISM® 7900 HT or 7700 using the
following conditions; 50°C for 2 min, 95°C for 10 min
followed by 40 cycles of 95°C for 15 sec and 60°C for 1
min. Samples were assayed in triplicate for each gene, and
the mean expression was used during subsequent analy-
sis. Analyses were done with the Applied Biosystems SDS
7900 or 7700 system software, version 2.2 or 1.2, respec-
tively. Relative expression was calculated using the com-
parative  ∆∆CT  method (Bulletin #2, ABI, Foster City,
USA). In brief, the comparative method of analysis com-
pares the amounts of target gene expression relative to an
endogenous control, such as GAPDH, within a sample to
normalise the expression. Within a group of samples, one
appropriate sample is elected as a reference sample. Each
sample is then compared to the nominated reference sam-
ple to give the relative expression of the target gene com-
pared to this reference sample (see Table 3).
Results
Gene expression in HMEC-1 cells 24 hours post AdALK1QD 
infection
In order to evaluate gene expression specifically induced
by ALK1, and not by ALK5, HMEC-1 cells, a human
microvascular endothelial cell line [30], were infected
with the recombinant adenovirus AdALK1QD expressing
the constitutively active form of ALK1. HMEC-1 cells
infected with the empty adenovirus vector AdCMV3
served as reference. 24 hours after infection total RNA was
isolated and used for hybridization on an Affymetrix
HuGeneFL GeneChip™ representing over 5,600 genes.
This experiment was produced in triplicate, and only
genes that showed at least a two-fold expression change
were considered for further evaluation. 11 genes displayed
more than a 2-fold increase in all three experiments. 22
Table 2: List of genes analysed by qRT-PCR and the 
corresponding pre-designed gene-specific primer pair assay (ABI 
Assay-on-Demand™, Applied Biosystems). Where possible RNA 
specific assays were selected which are depicted by _m1 suffix. 
For CHOP _g1 suffix signifies that the assay may detect DNA and 
for ID1 the _s1 suffix indicates both the primers and probe are in 
a single exon.
GENE ABI Assays-on-Demand™
ALK1/ACVRL1 Hs00163543_m1
ALK5/TGFBR1 Hs0061319_m1
BMP6 Hs00233470_m1
CARP Hs00173317_m1
CD148/HPTPη Hs00174561_m1
CHOP/DDIT3/GADD153 Hs00358796_g1
C-MYC Hs00153408_m1
Collagen VαI/COL5A1 Hs00609088_m1
Endoglin/ENG Hs00164438_m1
Endothelin/END1 Hs00174961_m1
HEFI/NEDD9 Hs00610590_m1
ID1 Hs00704053_s1
IL-8 Hs00174103_m1
SMAD6/MADH6 Hs00178579_m1
TGFβR2 Hs00559661_m1
TLR4 Hs00152939_m1
GAPDH Hs99999905_m1
Table 3: The selection of reference samples used for each of the comparative analyses for relative gene expression calculation based 
on qRT-PCR.
Reference samples: Test samples:
HMEC-1 + AdCMV3 24 hr; Experiment 1
HMEC-1 + AdCMV3 24 hr; Experiment 2
HMEC-1 + AdCMV3 24 hr; Experiment 3
HMEC-1 + AdALK1QD 24 hr; Experiment 1
HMEC-1 + AdALK1QD 24 hr; Experiment 2
HMEC-1 + AdALK1QD 24 hr; Experiment 3
HMEC-1 + AdCMV3 4 hr; Experiment 1
HMEC-1 + AdCMV3 4 hr; Experiment 2
HMEC-1 + AdALK1QD 4 hr; Experiment 1
HMEC-1 + AdALK1QD 4 hr; Experiment 2
HUVEC, no virus HUVEC + AdCMV3
HUVEC + AdALK1QD
ECRF24 cells no virus ECRF24 + AdLacZ
ECRF24 + AdALK1QD
HMEC-1 no TGF-β1, 16 hr incubation HMEC-1, 0.5 ng/ml TGF-β1, 16 hr incubation
HMEC-1, 4.0 ng /mlTGF-β1, 16 hr incubation
HMEC-1 no TGF-β1, 24 hr incubation HMEC-1, 0.5 ng /mlTGF-β1, 24 hr incubation
HMEC-1, 4.0 ng/ml TGF-β1, 24 hr incubationBMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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genes showed increased expression in two out of three
experiments. 15 genes were up-regulated by 2-fold or
more in the first two replicate experiments, and 4 genes
were up-regulated by ≥ 2-fold in replicate experiments 1
and 3. Three genes were up-regulated by ≥ 2-fold in repli-
cate experiments 2 and 3. We tried to identify genes that
were down-regulated by ALK1 signalling but there was no
consistent expression pattern of down-regulated genes
among the three experiments. Table 4 lists all the genes
up-regulated by ≥ 2-fold in at least two out of three exper-
iments. Genes are arranged according to groupings based
on current known biological functions.
Highest induction in all three experiments was seen for a
probe with no assigned GenBank number named by
Affymetrix as oncogene TLS/CHOP  suggesting that this
probe represents a fusion gene. Other names for CHOP
are  DDIT3  or  GADD153. sqRT-PCR revealed that
GADD153 was the gene in question and not TLS (data not
shown). Therefore, all further analyses were done for
GADD153.
To validate the gene array results we performed qRT-PCR
and sqRT-PCR for a subset of genes using the same RNA
that was used for the GeneChip™ hybridizations. qRT-PCR
was done for genes up-regulated in all three experiments
as well as for BMP6 (increased expression only seen in
experiment 1 and 2), ALK5, TβRII, endoglin and c-myc. Our
gene array data did not suggest an influence of ALK1 on
endoglin or c-myc expression but previous microarray data
had shown that ALK1 signalling up-regulates endoglin in
primary HUVECs [35] and down-regulates c-myc in pri-
mary dermal microvascular endothelial cells [36].
Because, TGF-β1 is known to induce its own receptors
[37], ALK5 and TβRII expression was also examined by
qRT-PCR. Also tested by sqRT-PCR was the chemokine
MGSA/GROα that had shown increased expression only
in two out of three experiments. qRT-PCR revealed that
endoglin and BMP6 expression was increased by more than
2-fold in all three experiments (Table 4). Up-regulated
expression in all three experiments was also seen for
MGSA/GROα  (data not shown). Expression values for
ALK5, TβRII and c-myc were unchanged across methods.
The ectopic expression of ALK1 due to AdALK1QD infec-
tion was not detected by GeneChip™ hybridization in the
first two experiments. The ABI qRT-PCR assay for ALK1 is
designed against exon 1/exon 2 but the coding sequence
for  ALK1  starts in exon 2. Thus, the ABI assay
Hs00163543_m1 will not detect ALK1 expression from
the AdALK1QD construct, since this one contains only the
ALK1  coding sequence. qRT-PCR assays with primers
located in exon 7/exon 8 (own assay) revealed ALK1
expression in all three experiments with a mean expres-
sion level of RQ = 5079.92 (8659.09/2475.21/4105.47)
confirming high levels of ectopic ALK1QD expression.
Gene expression in HMEC-1 cells 4 hours post AdALK1QD 
infection
The previous experiments assayed ALK1 induced gene
expression after 24 hours. In order to identify ALK1 early
response genes, HMEC-1 cells were infected with
AdALK1QD and RNA was isolated 4 hours post-infection.
AdCMV3 infected HMEC-1 cells served as reference. The
isolated RNA of two independent experiments was used
for Affymetrix HuGeneFL GeneChip™ analysis as well as
for qRT-PCR analysis for a selected set of genes (genes up-
regulated after 24 hours in all three experiments). By qRT-
PCR analysis AdALK1QD  infected cells showed high
ectopic  ALK1  expression (own qRT-PCR assay) with a
mean level of RQ = 157.795. Most of the genes identified
to be up-regulated after 24 hours showed no significant
changes over controls after 4 hours except for IL-8 (RQ =
0.595) and GADD153 (RQ = 0.69), which were consist-
ently down-regulated. This time dependent response sug-
gests that there is an early response component to ALK1
signalling for IL-8 and GADD153 but their subsequent up-
regulation after 24 hours might be an indirect effect of
prolonged ALK1 signalling.
Affymetrix HuGeneFL GeneChip™ analysis identified 13
genes to be up-regulated by more than 1.5-fold and 2
genes were down-regulated by more than 1.5-fold in both
experiments (see Table 5). For the purpose of identifying
early response genes the threshold for fold changes in
gene expression was this time set to 1.5. ALK1 expression
levels were measured to be 53.85 (experiment 1: 58.5;
experiment 2: 49.2). Thus, both the GeneChip™ hybridi-
zation and qRT-PCR methods demonstrated high ectopic
ALK1QD expression levels already after 4 hours of viral
infection. Of the genes up-regulated after 24 hours only
two genes, SMAD7 and KPNA3, showed increased expres-
sion after 4 hours suggesting these genes were directly reg-
ulated by ALK1 signalling. The identified early response
genes can be roughly divided into four functional groups:
transcription factors (REST,  TEAD4  and  NFIB), vesicle
transport/protein sorting (RAB6A, TM9SF2 and PICALM),
targeted protein degradation (CUL4A, COPS6), and sig-
nalling (KPNA3,  SMAD7,  GNA13,  NF2,  PLCL1).
LOC400986 and BCAT1 are classified as miscellanous due
to the lack of clear functional data to our knowledge.
Gene expression in AdALK1QD infected ECRF24 cells and 
primary HUVECs
To determine if different endothelial cell types react differ-
ently to ALK1 signalling we compared AdALK1QD-infected
ECRF24 and primary HUVEC cells versus HMEC-1 cells.
We used cells infected with AdCMV3 or the same vector
containing an irrelevant gene, LacZ (AdLacZ), as controlsB
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Table 4: Constitutively active ALK1 regulated gene expression in HMEC-1 cells after 24 hours. Gene expression profiling by Affymetrix GeneChip™ and qRT-PCR analysis for 
HMEC-1 cells (human microvascular endothelial cell line) infected with empty adenovirus (AdCMV3) or AdALK1QD. Listed are genes up-regulated in at least two out of three 
independent experiments. Cells were infected with an MOI of ~50. Gene expression was assesed after 24 hours. Gene expression profile of AdCMV3 infected cells served as 
reference. GeneChip™ raw data was analysed using Affymetrix MAS 4.0 comparison analysis. Listed are the mean results. Information about gene function was taken from 
NCBI Entrez Gene data base if not otherwise indicated. qRT-PCR based relative gene expression was calculated using the comparative ∆∆CT method. RQ represents the 
relative expression level (fold change) compared to the reference sample. RQMax/Min are the relative maximum/minimum expression levels of the mean expression level RQ.
Gene/Gene aliases [GenBank number]
Transcription factors Gene description GeneChip™fold 
change (StdDev)
qRT-PCR RQ 
(RQMax/Min)
TGF-β regulated 
(Ref.)
Inhibitor of DNA binding 1 (ID1) (represents [S78825]) role in cell growth, senescence, and differentiation, 
involved in angiogenesis
2.86 (0.71) 6.56 (9.83/4.42) [6, 70]
Inhibitor of DNA binding 1B (ID1B) [S78825] role in cell growth, senescence, and differentiation, 
involved in angiogenesis
14* nt -
Inhibitor of DNA binding 2 (ID2) [M97796] role in cell growth and differentiation 17.6* nt [70]
Inhibitor of DNA binding 2B (ID2B) [M96843] function unknown 8.15* nt -
Ankyrin repeat domain 1 (ANKRD1)/CARP [X83703] endothelial and smooth muscle cell expression, angiogenic 
activity [71]
4.46 (2.80) 4.29 (13.70/2.41) [41]
High mobility group AT-hook 2 (HMGA2) [U28749] HMG proteins are essential components of the 
enhancesome, may act as a transcriptional regulating factor
6* nt -
Signalling molecules
Interleukin 8 (IL-8) [M28130] inflammatory response, angiogenic factor 18.26 (10.83) 1056.07 (1686.10/
666.22)
[72-74]
Endothelin (EDN1)/ET-1 [J05008] vaso constrictor, involved in angiogenesis 3.36 (0.30) 3.87 (5.16/2.97) [75]
Chemokine (C-X-C motif) ligand 1 (CXCL1)/GROα1/MGSA 
[X54489]
immune response, tumor progression, angiogenic activity 8.2* nt [70]
Bone morphogenetic protein 6 (BMP6) [M60315] induced by proinflammatory cytokines, involved in bone 
and cartilage development
3.8* 4.26 (5.60/3.30) [70, 76]
Heme oxygenase-1 (HO-1) [X06985] heme catabolism, beneficial in cerebrovascular events, 
vasodilator
3.8* nt [77]
Jagged 1 (JAG1) [U73936] ligand for notch 1, involved in angiogenesis 3.9* nt [78]
Parathyroid hormone-like hormone (PTHLH) [M24351] involved in cell proliferation, apoptosis, cancer 2.35* nt [79, 80]
Signal transduction/regulation
SMAD6 [U59914] inhibitor of TGF-β family member signaling 2 14.2 (9.41) 14.56 (18.63/11.63) [81]
Toll-like receptor 4 (TLR4) [U93091] LPS innate immune response 4.33 (1.19) 3.98 (5.51/2.92) -
Protein tyrosine phosphatase, receptor type, J (PTPRJ)/CD148/
HPTPη [D37781]
involved in cell proliferation, differentiation, cell motility 3.56 (1.58) 2.08 (3.01/1.47) -
SMAD7 [AF010193] inhibitor of TGF-β family member signaling 2 7.2* nt [81]
Ras homolog gene family, member B (RHOB) [M12174] role in endosomal trafficking [82] 3.25* nt [70]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) 
[U67156]
activates c-Jun N-terminal kinase (JNK) 3.2* nt -
Endoglin (ENG)/CD105 (J05481) TGF-β1, -β3 accessory receptor and signaling modulator nd 2.36 (3.08/1.84) [83]
Extracellular matrixB
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Collagen 5α1 (COL5A1) [D90279] controls the initiation of collagen fibril assembly [62] 7.13 (4.27) 2.28 (2.93/1.81) [59, 60]
Serine (or cysteine) proteinase inhibitor 1 (SERPINH1)/HSP47 
[D83174]
assists maturation of the ECM protein type I collagen 2* nt [58]
Stress response
DNA-damage-inducible transcript 3 (DDIT3)/ GADD153 
[S40706]
transcription factor, associated with cell stress and 
apoptosis
19.5 (2.60) 4.55 (6.42/3.27) -
DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1) 
D85429]
linked to the 26S proteasome, up-regulated in bipolar 
disorder
3.03 (1.00) nt -
Homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 (HERPUD1) [D14695]
linked to the 26S proteasome, up-regulated by Wnt-1 4.1* nt -
Cell adhesion and cytoskelet
Neural precursor cell expressed, developmentally down-
regulated 9 (NEDD9)/ HEF1 [L43821]
actin filament bundle formation, cell adhesion, cytoskeleton 
organization and biogenesis, integrin mediated signalling 
pathway, regulation of cell cycle, regulation of cell growth, 
signal transduction
5.8 (0.95) 3.93 (5.74/2.73) [84]
Crystallin, alpha B (CRYAB) [S45630] member of the small heat shock protein (HSP20) family, 
assists assembly of desmin filaments [85]
11.1* nt [85, 86]
Tropomyosin 1 (alpha) (TPM1), splice variant 2 associated with the actin filaments 2.3* nt [87, 88]
Poliovirus receptor (PVR)/CD155 [M24407] also involved in the regulation of cell adhesion and cell 
motility [89]
2.35* nt -
Solute carrier family 3, member 2 (SLC3A2)/CD98 [M21904] activator of dibasic and neutral amino acid transport, 
mediates integrin signaling [90]
2.5* nt -
Miscellanous
Leukocyte receptor cluster (LRC) member 4 (LENG4) [S82470] Over-expressed in bladder and breast carcinoma 2.1* nt -
Karyopherin alpha 3 (KPNA3) [Y12394] nuclear transport protein 91a 2.75* nt -
Ankyrin repeat domain 15 (ANKRD15) [D79994] plays a role in cell growth 2.3* nt -
Squalene epoxidase (SQLE) [D78129)] catalyzes the first oxygenation step in sterol biosynthesis 2.45* nt -
The measurements of fold-change with a ~symbol in front of them are an approximation because the average difference in the reference samples were not above background; *mean of two 
experiments; nd, not detected; nt, not tested.
Table 4: Constitutively active ALK1 regulated gene expression in HMEC-1 cells after 24 hours. Gene expression profiling by Affymetrix GeneChip™ and qRT-PCR analysis for 
HMEC-1 cells (human microvascular endothelial cell line) infected with empty adenovirus (AdCMV3) or AdALK1QD. Listed are genes up-regulated in at least two out of three 
independent experiments. Cells were infected with an MOI of ~50. Gene expression was assesed after 24 hours. Gene expression profile of AdCMV3 infected cells served as 
reference. GeneChip™ raw data was analysed using Affymetrix MAS 4.0 comparison analysis. Listed are the mean results. Information about gene function was taken from 
NCBI Entrez Gene data base if not otherwise indicated. qRT-PCR based relative gene expression was calculated using the comparative ∆∆CT method. RQ represents the 
relative expression level (fold change) compared to the reference sample. RQMax/Min are the relative maximum/minimum expression levels of the mean expression level RQ. BMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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for bystander effects of viral infection. Non-infected
ECRF24 cells and HUVECs served as reference.
Infection with recombinant control adenoviruses had no
effect on IL-8 or GADD153, whereas it appears as if viral
infection leads to decreased HEF1, CARP, ALK5 and ALK1
expression in HUVECs as well as ECRF24 cells. Constitu-
tively active ALK1 signalling induced different gene
expression responses in ECRF24 cells, HUVECs and
HMEC-1 cells (see Table 6). ALK1QD  up-regulated
GADD153, IL-8, SMAD6, and ID1 in all three endothelial
cell types. Increased expression of TLR4, endothelin, CARP
and  endoglin  was only seen for primary HUVECs and
HMEC-1 cells but not for ECRF24. In contrast, increased
HEF1 expression by more than 3-fold was observed for
ECRF24 and HMEC-1 cells but not for primary HUVECs.
Furthermore, constitutively active ALK1 signalling
decreased TβRII expression in ECRF24, but not HUVECs
or HMEC-1 cells, and ALK5 expression was completely
blocked in primary HUVECs, but unchanged in ECRF24
and HMEC-1 cells. These results suggest that within the
endothelial cell lineage there is a notable cell type differ-
ence in ALK1-induced gene expression.
TGF-β1 regulated gene expression of ALK1 response genes 
in HMEC-1 cells
Thus far, ALK1 response genes were induced by a consti-
tutively active ALK1 that does not require ligand binding
for signal initiation. Since ALK1 is a TGF-β1 receptor, we
wanted to know if these genes become regulated by TGF-
β1, and in particular whether there are any differences
between high or low concentrations of TGF-β1, which
Table 5: Constitutively active ALK1 regulated gene expression in HMEC-1 cells after 4 hours. Gene expression profiling by Affymetrix 
GeneChip™ analysis for HMEC-1 cells (human microvascular endothelial cell line) infected with empty adenovirus (AdCMV3) or 
AdALK1QD. Cells were infected with an MOI of ~50. Gene expression was assessed after 4 hours. Gene expression profile of AdCMV3 
infected cells served as reference. GeneChip™ raw data was analysed using Affymetrix MAS 4.0 comparison analysis. Listed are the 
mean results of two independent experiments. Information about gene function was taken from NCBI Entrez Gene data base if not 
otherwise indicated.
Gene/Gene aliases [GenBank number] Gene description GeneChip™ fold change TGF-β regulated
RAS oncogene family member 6A (RAB6A) 
[M28212]
regulates a retrograde transport route 
connecting endosomes and the endoplasmic 
reticulum (ER) via the Golgi apparatus
4.35 (3.6/5.1) -
LOC400986 [U28831] protein immuno-reactive with anti-PTH 
polyclonal antibodies
4.1 (3.1/5.1) -
RE1-silencing transcription factor (REST) 
[U22314]
may function as a master negative-regulator of 
neurogenesis [92]; may play a role in vascular 
smooth muscle cells and human vascular 
disease [92, 93]
3.25 (1.8/4.7) -
Karyopherin alpha 3 (KPNA3) [Y12394] nuclear transport protein [91] 2.9 (3.1/2.7) -
Guanine nucleotide binding protein (G protein), 
alpha 13 (GNA13) [L22075]
plays a critical role in endothelial cells during 
vascular development, knock outs are 
embryonical lethal [54]
2.65 (1.8/3.5) -
Transmembrane 9 superfamily member 2 
(TM9SF2) [U81006]
may function as an endosome ion channel or 
small molecule transporter
2.45 (3.3/1.6) -
SMAD7 [AF010193] inhibitor of TGF-β family member signaling 2.35 (1.9/2.8) [81]
Cullin 4A (CUL4A) U58090] belongs to the cullin family of E3 ubiquitin 
ligases
2.3 (2.0/2.6) -
Branched-chain aminotransferase 1 (BCAT1) 
[U21551]
cytosolic and mitochondrial function, direct 
genetic target for Myc regulation
2.05 (1.8/2.3) -
Phosphatidylinositol-binding clathrin assembly 
protein (PICALM) [U45976]
involved in clathrin-mediated endocytosis 1.85 (2.1/1.6) -
TEA domain family member 4 (TEAD4) 
[U63824])
member of the transcriptional enhancer factor 
(TEF) family, directs muscle-specific gene 
expression, induces VEGF expression in 
endothelial cells [55]
1.8 (1.8/1.8) -
Nuclear factor I/B (NFIB) [U85193] essential for both lung maturation and brain 
development [94]
1.75 (1.8/1.7) -
COP9 constitutive photo-morphogenic homolog 
subunit 6 (COPS6) [U70735]
subunit of COP9 signalosome, involved in the 
regulation of Cullin-containing ubiquitin E3 
ligases [95]
1.7 (1.9/1.5) -
Neurofibromin 2 (NF2) similar to members of the ERM (ezrin, radixin, 
moesin) family, links cytoskeletal components 
with proteins in the cell membrane
-2.8 (1.6/4.0) -
Phospholipase C-like 1 (PLCL1) [D42108] involved in inositol phospholipid-based 
intracellular signaling cascade
-2.4 (2.3/2.5) -BMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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reportedly activate either the ALK5 or the ALK1 pathway
[6,29].
Approximately 80% confluent cells were incubated with
0.5 ng/ml or 4 ng/ml TGF-β1, respectively, for 16 hours
and 24 hours, respectively, which would reflect the time
intervall at which ALK1QD regulated gene expression was
assesed before. Expression levels of ALK1 response genes
were investigated by qRT-PCR and levels in TGF-β1-
treated cells were compared to non-TGF-β1 treated cells.
The expression profiles of TGF-β1 treated cells after 16
hours or 24 hours were almost identical regardless of TGF-
β1 concentration (Table 7, for simplification only the 24
hr expression levels are listed). Gene expression levels
with RQ values at or above 2 were considered to be
increased and RQ levels below 0.90 were considered to be
decreased. Four genes, COL5A1,  HEF1,  endothelin  and
BMP6 were up-regulated at both concentrations and time
points; surprisingly c-myc expression was also increased
being maximally up-regulated after 16 hours [RQ 1.66
(0.5 ng TGF-β1/ml) and RQ 1.99 (4 ng TGF-β1/ml)].
Three genes, GADD153,  IL-8  and  SMAD6  previously
shown to be up-regulated by constitutively active ALK1
showed suppression at all conditions. TLR4, CARP and
ID1 expression after 24 hours was decreased after treat-
ment with low TGF-β1 concentrations but unchanged
with high TGF-β1 concentrations. In summary, most of
the studied genes showed a distinct expression profile in
response to constitutively active ALK1 and TGF-β1 and
only COL5A1, HEF1, endothelin and BMP6 expression was
concordant.
TGF-β1 dose-dependent regulation of ALK1 response 
genes in primary HUVECs
Although it was reported that TGF-β1 regulates gene
expression differently in a dose dependent manner our
analyses for the ALK1 response genes did not reveal such
a regulatory mechanism for HMEC-1 cells. However, these
experiments were performed with a cell line and immor-
talized cells may act differently than primary cells as used
by Goumans and colleagues [6]. Thus, we used primary
HUVECs to investigate what effect different TGF-β1 con-
centrations might have on the expression of ALK1
response genes. Approximately 80% confluent primary
HUVECs were treated with different concentrations of
TGF-β1 (0.25 ng/ml, 0.5 ng/ml, 1 ng/ml, 4 ng/ml) for 16
hours. Gene expression levels of a selected set of genes
were compared to non-TGF-β1 treated cells by sqRT-PCR.
Table 6: Constitutively active ALK1 regulated gene expression in primary HUVECs and the HUVEC cell line ECRF24. ECRF24 cells 
were infected with an MOI of ~50 with the recombinant adenovirus AdLacZ, containing the LacZ gene, or AdALK1QD, respectively. 
Primary HUVECs were infected with an MOI of ~50 with the empty AdCMV3 adenovirus or AdALK1QD, respectively. Gene expression 
was assessed after 24 hours by qRT-PCR. Non-infected cells served as reference. qRT-PCR based relative gene expression was 
calculated using the comparative ∆∆CT method. RQ represents the relative expression level (fold change) compared to the reference 
sample. RQMax/Min are the relative maximum/minimum expression levels of the mean expression level RQ. The right column titled 
HMEC-1 shows in comparison the mean RQ level of three independent experiments with HMEC-1 cells infected with AdALK1QD (see 
Table 4). Genes with RQ values in bold are considered to be up-regulated.
ECRF24 primary HUVECs HMEC-1
Gene [GenBank number] AdLacZ RQ 
(RQMax/Min)
AdALK1QDRQ 
(RQMax/Min)
AdCMV3 RQ 
(RQMax/Min)
AdALK1QDRQ 
(RQMax/Min)
AdALK1QDRQ
GADD153 [S40706] 0.95 (1.07/0.85) 4.21 (5.27/3.37) 1.17 (1.27/1.07) 7.53 (12.05/4.70) 4.55
IL-8 [M28130] 1.13 (1.01/1.27) 11.55 (13.60/9.81) 1.52 (2.55/0.90) 4.37 (5.57/3.44) 1056.07
SMAD6 [U59914] 0.82 (0.90/0.75) 5.65 (6.59/4.84) 1.30 (1.44/1.17) 38.89 (44.26/34.18) 14.56
COL5A1 [D90279] 1.04 (1.15/0.94) 1.68 (1.94/1.45) 1.00 (1.10/0.92) 3.47 (4.06/2.96) 2.28
HEF1 [L43821] 0.89 (0.98/0.81) 3.88 (4.55/3.31) 0.61 (0.66/0.56) 1.18 (1.75/0.80) 3.93
TLR4 [U93091] 0.95 (1.06/0.85) 1.59 (1.82/1.39) 1.02 (1.12/0.93) 4.77 (5.70/3.99) 3.98
ET-1 [J05008] 0.64 (0.70/0.59) 0.73 (0.86/0.61) 1.07 (1.16/0.99) 2.21 (2.62/1.87) 3.87
CARP [X83703] 0.61 (0.74/0.50) 0.79 (1.08/0.58) 0.83 (1.00/0.69) 1.94 (2.82/1.33) 4.29
HPTPη [D37781] 1.69 (1.90/1.51) 1.54 (2.75/0.86) # # 2.08
ID1 [S78825] 0.70 (0.78/0.63) 2.06 (2.45/1.73) 1.40 (1.79/1.09) 4.04 (6.63/2.46) 6.56
BMP6 [M60315] 0.64 (0.70/0.57) 0.72 (0.82/0.63) 0.91 (1.15/0.73) 1.61 (2.04/1.27) 4.26
ALK5 [L11695] 0.68 (0.78/0.59) 0.95 (1.25/0.71) 0.41 (0.44/0.38) nd 1.36
TβRII [M85079] 1.18 (1.31/1.06) 0.77 (0.91/0.65) 0.96 (1.04/0.89) 1.38 (1.65/1.16) 1.26
Endoglin [J05481] 0.83 (0.93/0.74) 1.19 (1.60/0.89) 1.02 (1.10/0.95) 3.05 (4.07/2.29) 2.36
c-myc [V00568] 0.85 (1.03/0.70) 0.78 (0.90/0.67) 1.00 (1.17/0.86) 1.05 (1.64/0.67) 1.45
ALK1 [L17075] (ABI assay) 0.95 (1.09/0.83) 0.93 (1.11/0.77) 0.86 (0.93/0.79) 1.44 (2.28/0.91) 1.40
ALK1 [L17075] (own assay) 0.50 597.72* 0.55 197.18* 5079.92*
nd, not detected after 40 cycles; #, not detected after 40 cycles and not detected in the reference sample; *, ectopic expressionBMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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Several genes showed a clear concentration dependent bi-
phasic effect. Low TGF-β1 concentrations (0.25 ng/ml, 0.5
ng/ml) increased the expression of COL5A1,  HEF1,
HPTPη, DNAJB1/HSP40 and ALK1 whereas higher con-
centrations (1 ng/ml, 4 ng/ml) reduced expression, which
was most obvious at 4 ng/ml (Figure 1). A second group
of genes, IL-8, GADD153 and c-myc, were down-regulated
at all TGF-β1 concentrations. For a third group of genes,
TLR4 and ET-1, reduced expression was only observed at
4 ng/ml TGF-β1 and the expression of CARP  was not
changed by any of the TGF-β1 concentrations. SMAD6
showed a surprising expression pattern, being up-regu-
lated at the intermediate TGF-β1 concentration of 1 ng/ml
but was otherwise unaffected by any other concentration.
We also tested for MGSA but were unable to detect endog-
enous expression in HUVECs.
Discussion
The aim of this study was to identify genes that are regu-
lated by ALK1 signalling in endothelial cells. We were able
to identify 34 genes by Affymetrix GeneChip™ and qRT-
PCR analysis that were up-regulated in at least two out of
three independent experiments in HMEC-1 cells after 24
hours (Table 4) and 15 genes identified by GeneChip™
analysis being regulated after 4 hours (Table 5). Those
genes regulated after 4 hours are considered to be early
response genes and therefore are most likely direct targets
of ALK1 signalling, whereas the genes identified after 24
hours are either late response genes or are indirectly
effected by ALK1 signalling. Nevertheless, abrogated or
reduced ALK1 signalling would affect the expression of
early and late response genes as well as indirectly regu-
lated genes.
HHT is a vascular disorder of localized imbalanced angio-
genesis [38] caused by mutations in ALK1  or endoglin,
which implies that ALK1 signalling regulates angiogenesis
related genes. Indeed, several of the identified genes in our
study are reported to be involved in angiogenesis, tumor
angiogenesis and arteriogenesis, i.e. IL-8 [39], ET-1 [40],
CARP [41], HPTPη [42], ID1 [43,44], MGSA [45], SMAD7
[46],  HO-1  [47,48],  RHOB  [49],  PTHLH  [50,51],
SERPINH1/HSP47  [52],  JAG1  [53],  GNA13  [54] and
TEAD4  [55]. Animal studies for some of these genes
showed that gene deletion causes embryonic lethality in
mice that is accompanied by, or the result of, vascular
defects, in part similar to those seen in HHT mice models.
HPTPη homozygous mutant mice died before embryonic
day 11.5 with vascularisation failure marked by growth
Table 7: TGF-β1 regulated gene expression of ALK1 response genes in HMEC-1 cells. HMEC-1 cells (human microvascular endothelial 
cell line) were incubated with the indicated amounts of TGF-β1. Gene expression after 24 hours was assesed by qRT-PCR. Gene 
expression profile of non-TGF-β1 treated cells served as reference. qRT-PCR based relative gene expression was calculated using the 
comparative ∆∆CT method. RQ represents the relative expression level (fold change) compared to the reference sample. RQMax/Min are 
the relative maximum/minimum expression levels of the mean expression level RQ. The right column shows in comparison the 
average RQ level of three independent experiments with HMEC-1 cells infected with AdALK1QD (see Table 4). Genes with RQ values 
in bold are considered to be up-regulated and RQ values in italic are considered to be down-regulated.
HMEC-1
0.5 ng TGF-β1/ml 4 ng TGF-β1/ml AdALK1QD
Gene [GenBank number] 24 hours RQ (RQMax/Min) 24 hours RQ (RQMax/Min)R Q
GADD153 [S40706] 0.64 (1.55/0.27) 0.56 (0.74/0.43) 4.55
IL-8 [M28130] 0.17 (0.32/0.09) 0.14 (0.16/0.13) 1056.07
SMAD6 [U59914] 0.74 (0.83/0.66) 0.78 (0.87/0.69) 14.56
COL5A1 [D90279] 1.75 (2.00/1.53) 2.65 (3.51/2.01) 2.28
HEF1 [L43821] 3.26 (3.50/3.05) 3.37 (3.99/2.85) 3.93
TLR4 [U93091] 0.80 (1.05/0.61) 0.96 (1.07/0.87) 3.98
ET-1 [J05008] 3.27 (3.47/3.09) 3.06 (3.52/2.66) 3.87
CARP [X83703] 0.89 (1.21/0.65) 1.32 (2.41/0.72) 4.29
HPTPη [D37781] 0.94 (1.12/0.79) 1.14 (1.62/0.80) 2.08
ID1 [S78825] 0.72 (0.79/0.65) 0.91 (1.07/0.78) 6.56
BMP6 [M60315] 2.44 (2.72/2.19) 2.60 (2.82/2.39) 4.26
ALK5 [L11695] 1.07 (1.16/0.98) 1.43 (1.64/1.25) 1.36
TβRII [M85079] 0.97 (1.10/0.85) 0.99 (1.04/0.94) 1.26
Endoglin [J05481] 1.04 (1.22/0.88) 1.22 (1.29/1.16) 2.36
c-myc [V00568] 1.32 (1.71/1.02) 1.47 (1.88/1.16) 1.45
ALK1 [L17075] ABI assay 1.01 (1.23/0.83) 1.23 (1.45/1.04) 1.40
ALK1 [L17075] own assay 1.26 1.01 5079.92*
*, ectopic expressionBMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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retardation, disorganized vascular structures with a nota-
ble lack of endoglin expression, an increase in endothelial
cell numbers and mitotic activity. Mutant embryos
showed homogeneously enlarged primitive vessels defec-
tive in vascular remodelling and branching, similar to
endoglin-deficient embryos [42]. ID1 activates endothe-
lial cell proliferation and migration, represses the tran-
scription of the angiogenesis inhibitor thrombospondin-
1, and ID1 expression can be induced by VEGF and TGF-
β1 [43]. RHOB  null mice showed a retarded vascular
development characterized by altered sprout morphol-
ogy. Depletion of RhoB in neonatal rats is associated with
apoptosis in the sprouting endothelial cells of newly
forming vessels and similarly, in primary endothelial cell
culture models RhoB anti-sensense RNA treatment led to
apoptosis and failure in tube formation [49]. Jagged1
knock-out mice are embryonically lethal with vascular
remodelling defects [56]. Mutations in Jagged1 cause the
Alagille syndrome (AGS) a dominantly inherited multi-
system disorder. Intracranial bleeding is a recognized
complication and a cause of mortality in AGS due to
intracranial vessel abnormalities. There is a body of evi-
dence supporting a role for Jagged1 and the Notch signal-
ling pathway in vascular development, i.e. arterial-venous
TGF-β1 regulated gene expression in primary HUVECs Figure 1
TGF-β1 regulated gene expression in primary HUVECs. Primary HUVECs were treated for 16 hours with different 
TGF-β1 concentrations as indicated. Subsequently, RNA was isolated and gene expression for a set of genes was investigated 
by semi-quantitative RT-PCR. Expression levels for the GAPDH gene served as an internal control.BMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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differentiation [57]. TGF-β1 regulates the expression of
extracellular matrix (ECM) proteins.
We identified two genes, SERPINH1/HSP47 and COL5A1,
to be up-regulated by ALK1 that can be directly linked to
the ECM. The heat shock protein hsp47 is involved in the
maturation of the ECM protein type I collagen, both being
induced by TGF-β1 [58]. COL5A1 expression in osteob-
lasts and vascular smooth muscle cells is induced by TGF-
β1 [59,60] and haplo-insufficiency leads to the heritable
connective-tissue disorder Ehlers-Danlos syndrome that is
characterized by an altered collagen-fibrillar structure of
the dermis, joints, eyes and blood vessels [61]. COL5A1 -
/- mice are embryonially lethal around day E10 and death
is associated with pooling of blood in the yolk sac, sug-
gesting an insufficient wall integrity to maintain a func-
tioning yolk sac [62]. Mis-expression of Smad7 gave rise
to dilated large vessels in the developing chick limb and
head, and development of intra and intervascular shunts
were frequently observed [46]. It is noteworthy that the
ALK1 early response gene TEAD4/RTEF-1 is a transcription
factor that stimulates VEGF expression and thus promotes
endothelial migration and tube formation [54].
The cumulative developmental and biological data for the
above described proteins and the fact that their genes are
ALK1-regulated suggests that ALK1 is part of an inter-
dependent network in vascular homeostasis. This might
explain the vascular defects observed in HHT patients and
HHT mice models. Many of these genes may be potential
candidates in the search for HHT modifier genes. Thus, it
would be important now to investigate the expression
profile of these genes in the HHT endoglin and ALK1 mice
models as well as in HHT patients. Furthermore, the
ALK1-response genes endothelin (ET-1),  heme oxygenase
(HO-1) and BMP6 might also be involved in other vascu-
lar disorders. For example, patients with ALK1 mutations
were reported with overlapping symptoms for HHT and
primary pulmonary hypertension [63] a disorder effecting
endothelial as well as smooth muscle cells. Endothelin
and heme oxygenase play a role in vascular tone regula-
tion [64,65] and BMP6 is involved in vascular smooth
muscle cell differentiation and being an antagonist of
TGF-β1 [66].
ALK1 is a TGF-β1 receptor. We therefore performed a lit-
erature search to see which one of the ALK1 regulated
genes were reported to be TGF-β1 response genes. We
found reports for 19 genes to be regulated by TGF-β1
(Table 4 and 5). Furthermore, our sqRT-PCR results for
primary HUVECs (Figure 1) demonstrate that GADD153,
HPTPη, TLR4 and DNAJB1 expression is also regulated by
TGF-β1 adding these genes to the list of TGF-β1 response
genes while the remaining genes might be new target
genes of TGF-β s or BMPs. In addition, expression of sev-
eral ALK1-response genes in primary HUVECs are regu-
lated by TGF-β1 in a concentration dependent bi-phasic
way (Figure 1), being up-regulated at lower TGF-β1 con-
centrations and down-regulated at high concentrations.
Such a TGF-β dose dependent response mechanism for
primary endothelial cells was reported previously [6],
showing that low TGF-β1 concentrations (0.25 ng/ml and
0.5 ng/ml) phosphorylated Smad1/5 and enhanced pro-
liferation and migration mediated by ALK1, whereas high
TGF-β1 concentrations (≥ 2.5 ng/ml) had the opposite
effect mediated by ALK5 due to phosphorylation of
Smad2/3. Further experiments are currently under way to
investigate how ALK1 might be involved in the bi-phasic
activity of TGF-β1 in regulating the here identified ALK1-
response genes. In addition, we show to our knowledge
for the first time, that ALK1  expression in primary
HUVECs is regulated by TGF-β1 (Figure 1).
We observed distinct gene expression responses upon
ALK1QD signalling among three different endothelial cell
types (Table 6, summarized in Table 8), two established
endothelial cell lines (HMEC-1, ECRF24) and primary
endothelial cells (HUVECs). Cell type differences within
the endothelial lineage were also observed for TGF-β1
induced gene expression in primary HUVECs and HMEC-
1 cells (summarized in Table 8). TGF-β1 regulated gene
expression in HMEC-1 cells did not follow the expression
pattern as seen for several genes in primary HUVECs. For
example, COL5A1 and HEF1 were up-regulated in HMEC-
1 cells at low and high TGF-β1 concentrations, but in
HUVECs these genes followed a dose dependent expres-
sion pattern. This difference between different endothelial
cell types might explain why there is only minimal over-
lap between our list of ALK1 regulated genes and previ-
ously published reports.
Lamouille and colleagues analysed ALK1 induced gene
expression of AdALK1QD infected primary dermal microv-
ascular endothelial cells after 15 hours [30], but there is
no overlap regarding the expression profile with our
study, and this was despite the HMEC-1 cell line being
derived from dermal microvascular endothelial cells. In a
study by Ota et al. [35], primary HUVECs were used to
establish an ALK1 regulated expression profile 48 hours
after AdALK1QD infection and only the increased expres-
sion for SMAD6, SMAD7, ID1, ID2 and endoglin agrees
with our study. The greatest agreement can be found with
a recent analysis by Wu et al. [67]. Here, AdALK1QD
infected human lung microvascular endothelial cells were
used to investigate ALK1 regulated gene expression com-
parable to the expression profile initiated after 4 hour
TGF-β1 treatment as stated by the authors. The authors
report increased expression for GADD153,  HEF1,
DNAJB1, HO-1, SMAD7, CRYAB, HERPUD1, LENG4 and
SERPINH1, like in our study but they did not findBMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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increased expression for endoglin, SMAD6 or ID1 or ID2 as
we and Ota et al. observed. However, several other genes
including TLR4, endoglin, JAG1, CD155 and KPNA3 which
we found to be increased by ALK1 were instead induced
by TGF-β1 in the study by Wu et al. Furthermore, they
showed that the profiles of genes regulated by TGF-β1,
ALK1 and ALK5 in lung microvascular endothelial cells
are distinct from each other, although some genes are reg-
ulated by all of them. This is similar to our data in that
there is a difference in TGF-β induced signalling and con-
stitutively active ALK1 signalling in HMEC-1 cells (Table
7, summarized in Table 8) and HUVECs. In HUVECs, con-
stitutively active ALK1 increased IL-8,  GADD153  and
CARP expression that were either repressed by TGF-β1 or
unchanged (Figure 1). How can this be explained? The
observed disparities might be due to ligand mediated
transient responses versus the sustained responses owing
to a constitutively active receptor. Signal intensity and
duration are important factors in signal specificity. It is
also possible that cell type dependent TGF-β1 acts
through Smad-dependent and Smad-independent path-
ways. Nevertheless, it can not be excluded that further
ALK1 ligands like TGF-β3 or may be BMP9 [68] exist that
initiate a different gene profile than TGF-β1. In addition,
it is also possible that ligand independent ALK1QD regu-
lated gene expression in endothelial cells might partly
reflect ALK1-specific responses (i.e. REST, NFIB, TEAD4,
NF2, HEF1) for other cell types like smooth muscle cells
or neuronal cells [69].
Conclusion
In conclusion, we have identified new ALK1 as well as
TGF-β1 response genes. Several of those are involved in
the different phases of angiogenesis. Being down-stream
of the ALK1 signalling pathway the expression of these
genes would be affected by ALK1 mutations suggesting
that these genes might be involved in the development of
HHT. In addition, we showed that ligand induced recep-
tor signalling and subsequent gene expression can be dif-
ferent from gene expression induced by constitutively
active receptor signalling. Therefore, the gene expression
results obtained from studies with constitutively active
receptors like ALK1QD help to identify new target genes
but the results may not necessarily reflect the ligand acti-
vated gene expression profile. This needs to be established
in further assays.
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Table 8: Overview of constitutively active ALK1 and TGF-β1 regulated gene expression in different endothelial cell types.
ALK1QD regulated gene expression low TGF-β1 conc. (≤ 0.5 ng/ml) high TGF-β1 conc. (≥ 1 ng/ml)
Gene HMEC-1 HUVEC ECRF24 HMEC-1 HUVEC HMEC-1 HUVEC
GADD153 up up up down down down down
IL-8 up up up down down down down
SMAD6 up up up down - down up
COL5A1 up up - up up up down
HEF1 up - up up up up down
TLR4 up up - down -- down
ET-1 up up - up - up down
CARP up up - down - - -
HPTPη up - - - up - down
ID1 up up up down nt - nt
BMP6 up - - up nt up nt
ALK5 - down - - nt - nt
TβRII -- down down nt - nt
Endoglin up up - - nt - nt
c-myc --- u p down up down
ALK1 --- - u p - down
up, up-regulated expression; down, down-regulated expression; -, unchanged expression; nt, not testedBMC Cardiovascular Disorders 2006, 6:13 http://www.biomedcentral.com/1471-2261/6/13
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